tradmap

RPID RAPID MICRO BIOSYSTEMS, INC.

$0.70 -5.07%

Data as of close

Healthcare · Laboratory Analytical Instruments

RAPID MICRO BIOSYSTEMS, INC. (RPID) is a healthcare company in the Laboratory Analytical Instruments industry, with a market capitalization of $35 million. Shares last traded at $0.70, 85.7% below their 52-week high. Over the past year the stock is down 75.9%. Net profit margin is -145.6%, below the peer median of 1.9%. Revenue grew 19.7% year over year.

Market Cap
$35M
Shares Out
50.2M
EPS (TTM)
-$1.10
P/E (TTM)*
—
P/S Ratio
1.00
P/B Ratio
1.98
Dividend / Share
—
Dividend Yield
—
52-Week High
$4.89
52-Week Low
$0.70
Volume (venue)
271
Avg Vol (3m, venue)
12,471.063

* P/E (TTM) = market cap ÷ net income over the trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year — the same basis as the peer table and the screener, so it can differ from price ÷ EPS.

Performance

1W
-10.47%
1M
-23.48%
3M
-66.31%
6M
-71.86%
YTD
-75.59%
1Y
-75.92%

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)
24.92
SMA (50)
$1.08
SMA (200)
$2.23
Price vs SMA50
-34.84%
Price vs SMA200
-68.54%
ATR (14)
$0.05

Full technical analysis (26 indicators, D/W/M) →

Financials

Revenue
$35M
Net Income
-$51M
Gross Margin
—
Operating Margin
-141.5%
Net Margin
-145.6%
Return on Equity
-288.5%
Return on Assets
-87.6%
Current Ratio
2.55
Debt / Equity
1.08
Revenue Growth (YoY)
+19.7%

Trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year; revenue is the fiscal-year figure where quarterly revenue covers under half of it (typical for banks, insurers and REITs), and margins are taken on it; latest reported period ends 2026-06-30. Source: SEC EDGAR/XBRL.

Full financials — revenue, cash flow & debt over time →

Recent earnings

PeriodEPS (diluted)Reported
Q2 2026 -$0.27 2026-08-07
Q1 2026 -$0.31 2026-05-15
Q4 2025 (derived) -$0.26 2026-03-12
FY 2025 -$1.05 2026-03-12
Q3 2025 -$0.26 2025-11-07
Q2 2025 -$0.27 2025-08-12

Q4 marked "derived" = fiscal-year EPS minus Q1–Q3 (10-Ks report only the annual figure); EPS is not strictly additive, so it can differ by a cent or two from the issuer's own Q4.

Full earnings history →

Laboratory Analytical Instruments peers

RPID vs 14 industry peers (Laboratory Analytical Instruments), by market cap. Data as of close

P/S vs peers
1.00 / 4.80 med
-79% discount
Net margin vs peers
-145.6% / 1.9% med
below median
1–14 of 14
AAgilent Technologies$48.5B33.686.5819.5%-1.62%
WATWaters Corporation$44.2B68.719.5113.8%-2.86%
ILMNIllumina, Inc.$34.2B38.267.5519.7%-4.10%
MTDMettler Toledo$33.6B37.148.1421.9%+0.17%
RVTYRevvity$16.9B71.265.818.2%-3.38%
AVTRAvantor, Inc.$10.6B31.351.595.1%-2.86%
BIOBio-Rad Laboratories, Inc.$9.8B44.033.788.6%-1.57%
BRKRBruker Corp$8.5B—2.42-2.0%-2.48%
TXG10x Genomics, Inc.$8.0B—13.01-12.2%-12.14%
ALMRAlamar Biosciences, Inc.$2.0B———-5.48%
CTKBCytek Biosciences, Inc.$751M—3.63-32.2%-5.56%
PACBPacific Biosciences Of California, Inc.$727M———-10.34%
MASS908 Devices Inc.$421M—6.92-57.0%-9.26%
NAUTNautilus Biotechnology, Inc.$302M———-13.50%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.